Cihan Duran MD, Presenter: Nothing to Disclose

Dhaksina Moorty Ganeshan, Abstract Co-Author: Nothing to Disclose

James C. Yao, Abstract Co-Author: Consultant, Novartis AG Consultant, Pfizer Inc Consultant, Ipsen SA

Alexandria Phan, Abstract Co-Author: Research support, Novartis AG Consultant, Ipsen SA Research support, Ipsen SA

Chaan Ng MD, Abstract Co-Author: Nothing to Disclose

Evelyne Madeline Loyer MD, Abstract Co-Author: Research Consultant, Novartis AG

Chusilp Charnsangavej MD, Abstract Co-Author: Consultant, Novartis AG

1. To review the MR and CT imaging characteristics of hepatic metastasis from NET. 2. To discuss the pitfalls in the detection of these lesions 3. To discuss the pitfalls in the measurements of these lesions  

-- The clinical and surgical goal of imaging in metastatic liver disease from NET. -- The spectrum of MR and CT imaging characteristics of the NET’s metastases in liver. -- The various factors which may affect the detection and measurements of these lesion.  

Although most of the liver metastasis of NET are solid and hypervascular, they may show different imaging characteristics ranging from purely solid to purely cystic. Morphologic and enhancement characteristics may not be similar to the primary tumor also. Liver is the most common site for monitoring and evaluation of the therapeutic response in metastatic NETs. Multiple factors such as hepatosteatosis, hepatic venous congestion , arterioportal shunts related to the hypervascular metastasis and posttherapeutic perfusion changes can affect the lesion detection and measurement.

Duran, C, Ganeshan, D, Yao, J, Phan, A, Ng, C, Loyer, E, Charnsangavej, C, Spectrum of Hepatic Metastases from Neuroendocrine Tumors (NETs) and Pitfalls of the Detection and Measurements of the Lesions.  Radiological Society of North America 2012 Scientific Assembly and Annual Meeting, November 25 - November 30, 2012 ,Chicago IL. http://archive.rsna.org/2012/12024093.html